Amphivena Therapeutics Inc. Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Amphivena Therapeutics, Inc. is a clinical-stage, immuno-oncology company with a novel platform of T cell engagers (Amphivena ReSTORE™) that directly targets myeloid derived suppressor cells (MDSC), thus relieving cancer-induced immune suppression while controlling cytokine release syndrome (CRS).